EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

High CD38 expression defines a mitochondrial function-adapted CD8+ T cell subset with implications for lung cancer immunotherapy

Lei-Lei Lv, Jia-Wei Zhai, Jia-Juan Wu, Gui-Qin Fan, Yao-Xin Zhang, Yu Shen, Qiu-Xia Qu, Cheng Chen

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-024-03881-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Lei-Lei Lv und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Medicine, the First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215006, China. Hauptthemen laut MEDLINE: ADP-ribosyl Cyclase 1, CD8-Positive T-Lymphocytes, Lung Neoplasms, Mitochondria. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Suzhou Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite identifying specific CD8+T cell subsets associated with immunotherapy resistance, the molecular pathway triggering the process remains elusive. Given the potential of CD38 in regulating CD8+T cell function, we aimed to observe the accumulation of CD38+CD8+T cells in lung cancer and further explored its role in immunotherapy resistance. Phenotypic analysis of tumoral CD8+T cells from both lung cancer patients and immunotherapy-resistant pre-clinical models identifies that CD38-expressing CD8+T cells displayed as CD38hi and CD38intT cell subsets. Following, it was observed a higher expression of CD38 along with T cell exhaustion genes and dysregulated mitochondrial bioenergetics. In addition, it was suggested that an evaluated CD38hiCD8+T cells in peripheral but not in center of TME were associated with good response to anti-PD-1 therapy in NSCLC, as well as corresponding depth of clinical regression, which was evidenced by more depletion of CD38hiCD8+T cells occur in subject with higher regional CD38hiCD8+T cells infiltration. As expected, it was found that ICIs-resistant murine lung cancer models had lack of effective reduction in term of CD38hiCD8+T cells when receiving PD-L1 mAb alone. Notably, combination therapy of PD-L1 mAb and EGCG could selectively restrict CD38hiCD8+T cells infiltration and enhance IFN-γ production by these T cells, thereby significantly improved survival in this carcinoma model. This restored immunotherapy sensitivity was found to be related to the selective improved mitochondrial of CD38hiCD8+T cells, which was validated by the established link between IFN-γ production and mitochondrial metabolism. Collectively, our data highlighted a role for the CD38-coupled dysfunctional mitochondrial in promoting CD8+T cell exhaustion and intrinsic resistance to ICIs therapy, thereby offered a rationale target to enhance the therapeutic efficacy of PD-1 blockade therapy in lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADP-ribosyl Cyclase 1CD8-Positive T-LymphocytesLung NeoplasmsMitochondriaImmunotherapyAnimalsMiceHumansTumor MicroenvironmentMice, Inbred C57BLFemaleMembrane GlycoproteinsCarcinoma, Non-Small-Cell LungCell Line, TumorImmune Checkpoint InhibitorsT-Lymphocyte Subsets

Stichwörter der Autor:innen

CD38CD8+ T CellsImmune checkpoint blockadeLung cancerMitochondriaPD-1

Substanzen

ADP-ribosyl Cyclase 1CD38 protein, humanMembrane GlycoproteinsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Respiratory and Critical Medicine, the First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215006, China.
  • Respiratory Department, Xuzhou Central Hospital, 199 Jiefangnan Road, Xuzhou, 221000, China.
  • Clinical Immunology Institute, the First Affiliated Hospital of Soochow University, 178 Ganjiang Road, Suzhou, 215006, China.
  • Respiratory Department, Taicang Traditional Chinese Medicine Hospital, 140 Renmin South Road, Taicang, 215400, China.
  • Clinical Immunology Institute, the First Affiliated Hospital of Soochow University, 178 Ganjiang Road, Suzhou, 215006, China. qxqu@suda.edu.cn.
  • Department of Respiratory and Critical Medicine, the First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215006, China. chencheng@suda.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Suzhou Municipality

Zitieren

APA

Lv, L. L., Zhai, J. W., Wu, J. J., Fan, G. Q., Zhang, Y. X., Shen, Y., Qu, Q. X., & Chen, C. (2025). High CD38 expression defines a mitochondrial function-adapted CD8+ T cell subset with implications for lung cancer immunotherapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03881-5

Vancouver

Lv LL, Zhai JW, Wu JJ, Fan GQ, Zhang YX, Shen Y, et al. High CD38 expression defines a mitochondrial function-adapted CD8+ T cell subset with implications for lung cancer immunotherapy. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03881-5

BibTeX
@article{Lv2025,
  author = {Lv, Lei-Lei and Zhai, Jia-Wei and Wu, Jia-Juan and Fan, Gui-Qin and Zhang, Yao-Xin and Shen, Yu and Qu, Qiu-Xia and Chen, Cheng},
  title = {High CD38 expression defines a mitochondrial function-adapted CD8+ T cell subset with implications for lung cancer immunotherapy},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-024-03881-5}
}
Kostenlos starten →